Asset Details
Do you wish to reserve the book?
Liposomal Nanoparticle Delivery of Ginkgo Flavone Glycosides Enhances SIRT1 Activation and Improves Diabetic Cardiomyopathy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Liposomal Nanoparticle Delivery of Ginkgo Flavone Glycosides Enhances SIRT1 Activation and Improves Diabetic Cardiomyopathy
Do you wish to request the book?
Liposomal Nanoparticle Delivery of Ginkgo Flavone Glycosides Enhances SIRT1 Activation and Improves Diabetic Cardiomyopathy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Liposomal Nanoparticle Delivery of Ginkgo Flavone Glycosides Enhances SIRT1 Activation and Improves Diabetic Cardiomyopathy
2025
Overview
This study aims to explore the therapeutic mechanisms of Ginkgo Flavone Glycosides (GFGs) delivered via liposomal nanoparticles in treating Diabetic Cardiomyopathy (DCM) by upregulating Sirtuin 1 (SIRT1) to restore energy metabolism and autophagy homeostasis.
A DCM mouse model was employed, with groups treated with different doses of GFGs. Various evaluations, including body weight, blood glucose levels, and cardiac function, were performed. Network pharmacology, transcriptomic analysis, and molecular docking studies were conducted to elucidate the key role of SIRT1 in inhibiting DCM progression. In vitro experiments and proteomic sequencing were utilized to validate the regulatory effects of SIRT1.
The in vivo animal experiment results demonstrated that treatment with Ginkgo Flavone Glycosides (GFGs) significantly improved cardiac function in diabetic cardiomyopathy mice. Specifically, GFG treatment increased the left ventricular ejection fraction (LVEF) by approximately 81.3% compared to the Model+Lipo group, reduced the left ventricular internal diameter in systole (LVIDs) by approximately 69.2%, and decreased the left ventricular internal diameter in diastole (LVIDd) thickness by approximately 56.1%. Additionally, GFGs alleviated cardiomyocyte apoptosis, further supporting their therapeutic potential for diabetic cardiomyopathy. Bioinformatics analysis supported the regulation of DCM through the SIRT1/FOSL1/TSPAN4 axis. Proteomic data confirmed the beneficial effects of GFGs on diabetic cardiac energy metabolism and autophagy. Liposomal nanoparticles loaded with GFGs significantly extended drug release to 72 hours. In vitro experiments highlighted the role of SIRT1 in modulating FOSL1 and TSPAN4 expression. Proteomic sequencing further validated the regulatory role of the SIRT1/FOSL1/TSPAN4 signaling pathway in DCM and suggested that GFGs might enhance energy metabolism and autophagy in diabetic hearts by activating SIRT1.
Liposomal nanoparticle delivery of GFGs was shown to enhance SIRT1 activation, leading to the deacetylation of FOSL1 and suppression of TSPAN4, ultimately improving energy metabolism and autophagy in DCM. This study introduces a novel potential strategy for the treatment of DCM.
Publisher
Dove Medical Press Limited,Taylor & Francis Ltd,Dove Press,Dove Medical Press
Subject
/ Animals
/ Diabetes
/ Diabetes Mellitus, Experimental - complications
/ Diabetic Cardiomyopathies - drug therapy
/ Diabetic Cardiomyopathies - metabolism
/ Ethylenediaminetetraacetic acid
/ Flavones
/ Flavones - administration & dosage
/ Glycosides - administration & dosage
/ Heart
/ Lipids
/ Male
/ Mice
/ Molecular Docking Simulation
/ Myocytes, Cardiac - drug effects
/ Nanoparticles - administration & dosage
/ Solvents
